A multicenter retrospective analysis of patients with nasopharyngeal carcinoma treated in IMRT era from a nonendemic population: Turkish Society for Radiation Oncology Head and Neck Cancer Group Study (TROD 01-001)

被引：1

作者：

Yildirim, Halil Cumhur ^{[1
]}

Kupik, Gulnihan Eren ^{[2
]}

Mustafayev, Teuta Zoto ^{[3
]}

Berber, Tanju ^{[4
]}

Yavuz, Berrin ^{[5
]}

Cetinayak, Oguz ^{[6
]}

Akagunduz, Ozlem ^{[7
]}

Bicakci, Beyhan Ceylaner ^{[8
]}

Arslan, Suheyla Aytac ^{[9
]}

Soykut, Ela Delikgoz ^{[10
]}

Gundog, Mete ^{[11
]}

Figen, Metin ^{[12
]}

Teke, Fatma ^{[13
]}

Canyilmaz, Emine ^{[14
]}

Birgi, Sumerya Duru ^{[15
]}

Duzova, Mursel ^{[16
]}

Igdem, Sefik ^{[17
]}

Abakay, Candan Demiroz ^{[18
]}

Atasoy, Beste ^{[19
]}

Kaydihan, Nuri ^{[20
]}

Parvizi, Murtaza ^{[21
]}

Uslu, Gonca Hanedan ^{[22
]}

Saginc, Halil ^{[23
]}

Akman, Fadime ^{[6
]}

Ozyar, Enis ^{[3
]}

机构：

[1] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Radiat Oncol, Istanbul, Turkiye

[2] Mugla Sitki Kocman Univ, Fac Med, Dept Radiat Oncol, Mugla, Turkiye

[3] Acibadem Univ, Fac Med, Dept Radiat Oncol, Istanbul, Turkiye

[4] Prof Dr Cemil Tascioglu City Hosp, Dept Radiat Oncol, Istanbul, Turkiye

[5] Necmettin Erbakan Univ, Meram Fac Med, Dept Radiat Oncol, Konya, Turkiye

[6] Dokuz Eylul Univ, Fac Med, Dept Radiat Oncol, Izmir, Turkiye

[7] Ege Univ, Fac Med, Dept Radiat Oncol, Izmir, Turkiye

[8] Kartal Dr Lutfi Kirdar City Hosp, Dept Radiat Oncol, Istanbul, Turkiye

[9] Ankara City Hosp, Dept Radiat Oncol, Ankara, Turkiye

[10] Samsun Educ & Res Hosp, Dept Radiat Oncol, Samsun, Turkiye

[11] Erciyes Univ, Fac Med, Dept Radiat Oncol, Kayseri, Turkiye

[12] Sisli Hamidiye Etfal Educ & Res Hosp, Dept Radiat Oncol, Istanbul, Turkiye

[13] Dicle Univ, Fac Med, Dept Radiat Oncol, Diyarbakir, Turkiye

[14] Karadeniz Tech Univ, Fac Med, Dept Radiat Oncol, Trabzon, Turkiye

[15] Ankara Univ, Fac Med, Dept Radiat Oncol, Ankara, Turkiye

[16] Selcuk Univ, Fac Med, Dept Radiat Oncol, Konya, Turkiye

[17] Istanbul Bilim Univ, Gayrettepe Florence Nightingale Hosp, Dept Radiat Oncol, Istanbul, Turkiye

[18] Bursa Uludag Univ, Fac Med, Dept Radiat Oncol, Bursa, Turkiye

[19] Marmara Univ, Fac Med, Dept Radiat Oncol, Istanbul, Turkiye

[20] Istanbul Bahcelievler Mem Hosp, Dept Radiat Oncol, Istanbul, Turkiye

[21] Manisa City Hosp, Dept Radiat Oncol, Manisa, Turkiye

[22] Trabzon Kanuni Educ & Res Hosp, Dept Radiat Oncol, Trabzon, Turkiye

[23] Pamukkale Univ, Fac Med, Dept Radiat Oncol, Denizli, Turkiye

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2023年 / 45卷 / 05期

关键词：

chemoradiotherapy; EBV-DNA; intensity-modulated radiotherapy; nasopharyngeal carcinoma; nonendemic; INTENSITY-MODULATED RADIOTHERAPY; AJCC/UICC STAGING SYSTEM; CONCURRENT CHEMORADIOTHERAPY; 8TH EDITION; CHEMOTHERAPY; DNA; VALIDATION; OUTCOMES; TRIALS; AREAS;

D O I：

10.1002/hed.27333

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

BackgroundWe aimed to evaluate patients with nasopharyngeal carcinoma (NPC) in a nonendemic population. MethodsIn a national, retrospective, multicenteric study, 563 patients treated with intensity modulated radiotherapy at 22 centers between 2015 and 2020 were analyzed. ResultsMedian age was 48 (9-83), age distribution was bimodal, 74.1% were male, and 78.7% were stage III-IVA. Keratinizing and undifferentiated carcinoma rates were 3.9% and 81.2%. Patients were treated with concomitant chemoradiotherapy (48.9%), or radiotherapy combined with induction chemotherapy (25%) or adjuvant chemotherapy (19.5%). After 34 (6-78) months follow-up, 8.2% locoregional and 8% distant relapse were observed. Three-year overall survival was 89.5% and was lower in patients with age >= 50, male sex, keratinizing histology, T4, N3 and advanced stage (III-IVA). ConclusionsPatients with NPC in Turkey have mixed clinical features of both east and west. Survival outcomes are comparable to other reported series; however, the rate of distant metastases seems to be lower.

引用

页码：1194 / 1205

页数：12

共 38 条

[1] Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099
Al-Sarraf, M
LeBlanc, M
Giri, PGS
Fu, KK
Cooper, J
Vuong, T
Forastiere, AA
Adams, G
Sakr, WA
Schuller, DE
Ensley, JF
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1310 - 1317
[2] Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area
Alfieri, Salvatore
Iacovelli, Nicola Alessandro
Marceglia, Sara
Lasorsa, Irene
Resteghini, Carlo
Taverna, Francesca
Mazzocchi, Arabella
Orlandi, Ester
Guzzo, Marco
Bianchi, Roberto
Fanti, Diana
Pala, Laura
Racca, Sara
Dvir, Roee
Quattrone, Pasquale
Gloghini, Annunziata
Volpi, Chiara Costanza
Granata, Roberta
Bergamini, Cristiana
Locati, Laura
Licitra, Lisa
Bossi, Paolo
[J]. ONCOTARGET, 2017, 8 (29) : 47780 - 47789
[3] Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study)
Au, K. H.
Ngan, Roger K. C.
Ng, Alice W. Y.
Poon, Darren M. C.
Ng, W. T.
Yuen, K. T.
Lee, Victor H. F.
Tung, Stewart Y.
Chan, Anthony T. C.
Sze, Henry C. K.
Cheng, Ashley C. K.
Lee, Anne W. M.
Kwong, Dora L. W.
Tam, Anthony H. P.
[J]. ORAL ONCOLOGY, 2018, 77 : 16 - 21
[4] Bimodal age distribution in Hodgkin's disease and nasopharyngeal carcinoma
Barista, Ibrahim
Varan, Ali
Ozyar, Enis
[J]. MEDICAL HYPOTHESES, 2007, 68 (06) : 1421 - 1421
[5] Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients
Baujat, B
Audry, W
Bourhis, J
Chan, ATC
Onat, H
Chua, DTT
Kwong, DLW
al-Sarraf, M
Chi, KH
Hareyama, M
Leung, SF
Thephamongkhol, K
Pignon, JP
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (01): : 47 - 56
[6] Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort
Bossi, Paolo
Trama, Annalisa
Bernasconi, Alice
Grisanti, Salvatore
Mohamad, Issa
Galiana, Isabel L.
Ozyar, Enis
Franco, Pierfrancesco
Vecchio, Stefania
Bonomo, Pierluigi
Cirauqui, Beatriz C.
El-Sherify, Mustafa
Ursino, Stefano
Argiris, Athanassios
Pan, Jonathan
Wittekindt, Claus
D'Angelo, Elisa
Costa, Loredana
Buglione, Michela
Johnson, Jennifer
Airoldi, Mario
Mesia, Ricard
Resteghini, Carlo
Licitra, Lisa
Orlandi, Ester
[J]. EUROPEAN JOURNAL OF CANCER, 2021, 159 : 194 - 204
[7] Boussen Hamouda, 2012, Crit Rev Oncol Hematol, V84 Suppl 1, pe106, DOI 10.1016/j.critrevonc.2010.09.005
[8] Age-incidence curves of nasopharyngeal carcinoma worldwide: Bimodality in low-risk populations and aetiologic implications
Bray, Freddie
Haugen, Marion
Moger, Tron A.
Tretli, Steinar
Aalen, Odd O.
Grotmol, Tom
[J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (09) : 2356 - 2365
[9] Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial
Cao, Su-Mei
Yang, Qi
Guo, Ling
Mai, Hai-Qiang
Mo, Hao-Yuan
Cao, Ka-Jia
Qian, Chao-Nan
Zhao, Chong
Xiang, Yan-Qun
Zhang, Xiu-Ping
Lin, Zhi-Xiong
Li, Wei-Xiong
Liu, Qing
Qiu, Fang
Sun, Rui
Chen, Qiu-Yan
Huang, Pei-Yu
Luo, Dong-Hua
Hua, Yi-Jun
Wu, Yi-Shan
Lv, Xing
Wang, Lin
Xia, Wei-Xiong
Tang, Lin-Quan
Ye, Yan-Fang
Chen, Ming-Yuan
Guo, Xiang
Hong, Ming-Huang
[J]. EUROPEAN JOURNAL OF CANCER, 2017, 75 : 14 - 23
[10] Nasopharyngeal carcinoma
Chen, Yu-Pei
Chan, Anthony T. C.
Quynh-Thu Le
Blanchard, Pierre
Sun, Ying
Ma, Jun
[J]. LANCET, 2019, 394 (10192) : 64 - 80

← 1 2 3 4 →